MCID: MST002
MIFTS: 51

Mast-Cell Leukemia

Categories: Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Mast-Cell Leukemia

MalaCards integrated aliases for Mast-Cell Leukemia:

Name: Mast-Cell Leukemia 12 37 15
Leukemia, Mast-Cell 44 73
Mast Cell Leukemia 29 6
Leukemia Mast Cell 55

Classifications:



External Ids:

Disease Ontology 12 DOID:9254
ICD10 33 C94.3 C94.30
MeSH 44 D007946
NCIt 50 C3169
KEGG 37 H01511
UMLS 73 C0023461

Summaries for Mast-Cell Leukemia

Disease Ontology : 12 A leukemia that results in an overwhelming number of tissue mast cells located in peripheral blood.

MalaCards based summary : Mast-Cell Leukemia, also known as leukemia, mast-cell, is related to systemic mastocytosis and diffuse cutaneous mastocytosis. An important gene associated with Mast-Cell Leukemia is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways/superpathways are PI3K-Akt signaling pathway and ERK Signaling. The drugs Ketamine and Iron have been mentioned in the context of this disorder. Affiliated tissues include peripheral blood, myeloid and bone, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Mast cell leukemia is an extremely aggressive subtype of acute myeloid leukemia that usually occurs de... more...

Related Diseases for Mast-Cell Leukemia

Diseases related to Mast-Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Related Disease Score Top Affiliating Genes
1 systemic mastocytosis 32.7 KIT KITLG
2 diffuse cutaneous mastocytosis 32.4 ATP7A KIT
3 mast cell disease 32.3 KIT KITLG
4 aggressive systemic mastocytosis 30.8 KIT KITLG
5 urticaria pigmentosa 30.6 KIT KITLG
6 cutaneous mastocytosis 29.9 ATP7A KIT KITLG
7 asthma 28.8 CCL2 CCL5 KITLG RASGRP4
8 aleukemic mast cell leukemia 12.3
9 classic mast cell leukemia 12.2
10 mast-cell sarcoma 11.2
11 leukemia 10.7
12 indolent systemic mastocytosis 10.6 KIT KITLG
13 cutaneous solitary mastocytoma 10.6 KIT KITLG
14 ewing's family of tumors 10.6 KIT KITLG
15 dowling-degos disease 1 10.6 KIT KITLG
16 stachybotrys chartarum 10.4 CCL2 CCL5
17 piebald trait 10.4 KIT KITLG
18 congenital mesoblastic nephroma 10.4 KIT NTRK3
19 viral meningitis 10.4 CCL2 CCL5
20 polymorphous low-grade adenocarcinoma 10.4 KIT NTRK3
21 viral encephalitis 10.3 CCL2 CCL5
22 malignant mesenchymoma 10.3 KIT NTRK3
23 chikungunya 10.3 CCL2 CCL5
24 neurofibroma 10.2 KIT KITLG
25 myeloid leukemia 10.1
26 leukemia, acute myeloid 10.1
27 pulmonary vein stenosis 10.1 KDR KIT
28 senile angioma 10.1 KDR KIT
29 connective tissue cancer 10.0 KIT NTRK3
30 mast cell neoplasm 10.0 KIT KITLG NTRK3
31 gastrointestinal stromal tumor 10.0 KIT KITLG NTRK3
32 8p11 myeloproliferative syndrome 10.0 KDR KIT
33 fibrosarcoma of bone 10.0 KDR KIT
34 vascular cancer 9.9 KDR KIT
35 chronic myelomonocytic leukemia 9.9
36 pdgfrb-associated chronic eosinophilic leukemia 9.9
37 cavernous hemangioma 9.9 KDR KIT
38 leukocyte disease 9.8 KIT KITLG
39 leukemia, chronic lymphocytic 2 9.8
40 leukemia, chronic lymphocytic 9.8
41 reticulum cell sarcoma 9.8
42 hematopoietic stem cell transplantation 9.8
43 portal hypertension 9.8
44 sarcoma 9.8
45 urticaria 9.8
46 histiocytosis 9.8
47 sm-ahnmd 9.8
48 monocytic leukemia 9.8
49 leukemia, b-cell, chronic 9.8
50 maculopapular cutaneous mastocytosis 9.8

Graphical network of the top 20 diseases related to Mast-Cell Leukemia:



Diseases related to Mast-Cell Leukemia

Symptoms & Phenotypes for Mast-Cell Leukemia

GenomeRNAi Phenotypes related to Mast-Cell Leukemia according to GeneCards Suite gene sharing:

26 (show all 33)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 10.19 KDR BTK CCL2 KIT
2 Decreased viability GR00221-A-2 10.19 KDR BTK NTRK3
3 Decreased viability GR00221-A-3 10.19 KDR BTK
4 Decreased viability GR00221-A-4 10.19 KDR BTK CCL2 NTRK3
5 Decreased viability GR00301-A 10.19 BTK KIT
6 Decreased viability GR00402-S-2 10.19 KDR BTK CCL2 KIT NTRK3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.84 SYT1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.84 KIT BTK
9 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.84 SYT1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.84 BTK
11 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.84 KDR
12 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.84 SYT1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.84 NTRK3
14 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.84 BTK NTRK3
15 Increased shRNA abundance (Z-score > 2) GR00366-A-140 9.84 BTK
16 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.84 KIT NTRK3
17 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.84 KIT
18 Increased shRNA abundance (Z-score > 2) GR00366-A-162 9.84 SYT1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.84 KIT
20 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.84 SYT1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.84 BTK
22 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.84 KIT NTRK3
23 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.84 KDR
24 Increased shRNA abundance (Z-score > 2) GR00366-A-4 9.84 BTK
25 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.84 NTRK3
26 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.84 KIT NTRK3
27 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.84 BTK
28 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.84 KIT KDR BTK SYT1 NTRK3
29 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.84 KIT
30 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.84 KIT
31 Decreased substrate adherent cell growth GR00193-A-1 9.63 BTK KIT
32 Decreased substrate adherent cell growth GR00193-A-2 9.63 KIT
33 Decreased substrate adherent cell growth GR00193-A-4 9.63 BTK KIT KDR

MGI Mouse Phenotypes related to Mast-Cell Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.87 KDR KIT KITLG RASGRP4 SYT1 BTK
2 immune system MP:0005387 9.86 KIT KITLG RASGRP4 ATP7A BTK CCL2
3 liver/biliary system MP:0005370 9.55 KDR KIT KITLG SYT1 ATP7A
4 pigmentation MP:0001186 9.26 KIT KITLG RASGRP4 ATP7A
5 respiratory system MP:0005388 9.02 KDR KIT NTRK3 SYT1 ATP7A

Drugs & Therapeutics for Mast-Cell Leukemia

Drugs for Mast-Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Iron Approved Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
3
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
4
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
5 Analgesics Phase 3,Phase 2,Not Applicable
6 Central Nervous System Depressants Phase 3,Phase 1,Phase 2,Not Applicable
7 Neurotransmitter Agents Phase 3,Not Applicable
8 Anesthetics Phase 3
9 Anesthetics, Dissociative Phase 3
10 Anesthetics, General Phase 3
11 Anesthetics, Intravenous Phase 3
12 Peripheral Nervous System Agents Phase 3,Phase 2,Not Applicable
13 Excitatory Amino Acid Antagonists Phase 3
14 Excitatory Amino Acids Phase 3
15 ferric gluconate Phase 3
16 Ferric Compounds Phase 3
17 Narcotics Phase 3,Not Applicable
18 Hematinics Phase 3,Phase 2
19 Analgesics, Opioid Phase 3,Not Applicable
20 Iron Supplement Nutraceutical Phase 3
21
Sunitinib Approved, Investigational Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
22
Vidarabine Approved, Investigational Phase 2,Phase 1,Not Applicable 24356-66-9 32326 21704
23
alemtuzumab Approved, Investigational Phase 2 216503-57-0
24
Fludarabine Approved Phase 2,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
25
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
26
Denileukin diftitox Approved, Investigational Phase 2 173146-27-5
27
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
28
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1,Not Applicable 22916-47-8 4189
29
Busulfan Approved, Investigational Phase 2 55-98-1 2478
30
Bortezomib Approved, Investigational Phase 1, Phase 2 179324-69-7 387447 93860
31
Mycophenolic acid Approved Phase 2,Phase 1,Not Applicable 24280-93-1 446541
32
Mycophenolate mofetil Approved, Investigational Phase 2,Phase 1,Not Applicable 128794-94-5 5281078
33
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381
34
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
35
leucovorin Approved, Nutraceutical Phase 2,Phase 1,Early Phase 1 58-05-9 143 6006
36
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1,Early Phase 1 59-30-3 6037
37 Staurosporine Experimental Phase 2 62996-74-1
38
Doxil Approved June 1999 Phase 1, Phase 2 31703
39 4'-N-benzoylstaurosporine Phase 2
40 Specific substance maruyama Phase 2
41 Angiogenesis Inhibitors Phase 2,Phase 1
42 Angiogenesis Modulating Agents Phase 2,Phase 1
43 Protein Kinase Inhibitors Phase 2
44 Interleukin-2 Phase 2
45 Imatinib Mesylate Phase 2 220127-57-1 123596
46 Epoetin alfa Phase 2 113427-24-0
47 Alkylating Agents Phase 2
48 Chelating Agents Phase 2,Phase 1,Not Applicable
49 Folic Acid Antagonists Phase 2,Phase 1,Early Phase 1
50 Analgesics, Non-Narcotic Phase 2

Interventional clinical trials:

(show top 50) (show all 54)
# Name Status NCT ID Phase Drugs
1 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
3 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
4 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
5 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
6 Midostaurin in Indolent Systemic Mastocytosis Unknown status NCT01920204 Phase 2 Midostaurin,
7 Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Unknown status NCT01824615 Phase 2 Sunitinib
8 Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia Completed NCT00233454 Phase 2 Midostaurin
9 Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia Completed NCT01807598 Phase 2 brentuximab vedotin
10 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
11 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
12 Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) Completed NCT00493129 Phase 2 Ontak (Denileukin Diftitox)
13 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
14 Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer Completed NCT00627666 Phase 2 busulfan;fludarabine phosphate;leucovorin calcium;methotrexate
15 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
16 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
17 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
18 Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia Active, not recruiting NCT00782067 Phase 2 Midostaurin (PKC412)
19 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer Active, not recruiting NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
20 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis Not yet recruiting NCT03580655 Phase 2 Avapritinib
21 CD16/IL-15/CD33 Tri-Specific Killer Engagers (TriKes) for CD33+ Hem Malignancies Not yet recruiting NCT03214666 Phase 1, Phase 2 161533 Trike Phase I;161533 Trike Phase II
22 Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis Terminated NCT02415608 Phase 2 Ibrutinib
23 Sunitinib in Treating Patients With Idiopathic Myelofibrosis Terminated NCT00387426 Phase 2 sunitinib malate
24 Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies Withdrawn NCT01101412 Phase 1, Phase 2 Edetate Calcium Disodium;Ethanol;Trimethoprim-sulfamethoxazole
25 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01231919 Phase 1 Akt inhibitor MK2206
26 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy Completed NCT00890747 Phase 1 sunitinib malate
27 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies Recruiting NCT02561988 Phase 1 Avapritinib
28 A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Recruiting NCT02571036 Phase 1 DCC-2618
29 Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer Unknown status NCT01295463
30 Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial Unknown status NCT00897767
31 Patient-Reported Outcome Questionnaire for Systemic Mastocytosis Completed NCT02380222
32 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant Completed NCT01199562 Not Applicable ganciclovir;valganciclovir;foscarnet sodium
33 Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer Completed NCT01053494 Not Applicable
34 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer Completed NCT00112593 Not Applicable fludarabine phosphate;cyclosporine;mycophenolate mofetil
35 S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers Completed NCT00996047
36 Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone Completed NCT00993694 chemotherapy;dapsone
37 Quality of Life in Younger Leukemia and Lymphoma Survivors Completed NCT00956475
38 Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial Completed NCT00890435
39 Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases Completed NCT00376922 Not Applicable
40 Mast Cell Connect: A Registry for Patients With Mastocytosis Recruiting NCT02620254
41 Registry of Older Patients With Cancer Recruiting NCT01137825
42 Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer Recruiting NCT01137643
43 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer Recruiting NCT00935090 Not Applicable
44 Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia Active, not recruiting NCT01869777 Not Applicable
45 Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer Active, not recruiting NCT00898079
46 Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies Active, not recruiting NCT00014235 Not Applicable fludarabine phosphate;cyclosporine;mycophenolate mofetil
47 Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases Active, not recruiting NCT00424242 Early Phase 1 Pemetrexed
48 Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers Terminated NCT00952185 Not Applicable
49 Studying Fentanyl in Patients With Cancer Terminated NCT00899951 fentanyl citrate
50 Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer Terminated NCT00726830 Not Applicable methadone hydrochloride;morphine sulfate;oxycodone hydrochloride

Search NIH Clinical Center for Mast-Cell Leukemia

Cochrane evidence based reviews: leukemia, mast-cell

Genetic Tests for Mast-Cell Leukemia

Genetic tests related to Mast-Cell Leukemia:

# Genetic test Affiliating Genes
1 Mast Cell Leukemia 29

Anatomical Context for Mast-Cell Leukemia

The Foundational Model of Anatomy Ontology organs/tissues related to Mast-Cell Leukemia:

19
Peripheral Blood

MalaCards organs/tissues related to Mast-Cell Leukemia:

41
Myeloid, Bone, Bone Marrow, Monocytes

Publications for Mast-Cell Leukemia

Articles related to Mast-Cell Leukemia:

(show top 50) (show all 77)
# Title Authors Year
1
KIT D816V- chronic myelomonocytic leukemia progressing to KIT D816V+ associated to mast cell leukemia responding to allogeneic hematopoietic cell transplantation. ( 29151134 )
2018
2
Acute mast cell leukemia: A rare but highly aggressive hematopoietic neoplasm. ( 29736992 )
2018
3
Leukemic-phase progression of aleukemic mast cell leukemia. ( 29794078 )
2018
4
De novo mast cell leukemia without CD25 expression and KIT mutations: a rare case report in a 13-year-old child. ( 29458385 )
2018
5
<i>KIT</i> D816V Positive Acute Mast Cell Leukemia Associated with Normal Karyotype Acute Myeloid Leukemia. ( 29670776 )
2018
6
Infliction of proteotoxic stresses by impairment of the unfolded protein response or proteasomal inhibition as a therapeutic strategy for mast cell leukemia. ( 29423023 )
2018
7
A Case of Mast Cell Leukemia: A Review of the Pathophysiology of Systemic Mastocytosis and Associated Psychiatric Symptoms. ( 29571984 )
2018
8
Myelodysplasia and Mast Cell Leukemia with t(9;22). ( 29318069 )
2017
9
Highly Aggressive de novo Aleukemic Variant of Mast Cell Leukemia Without KIT D816V Mutation. ( 28840997 )
2017
10
Acute Mast Cell Leukemia Associated with t(4;5)(q21;q33). ( 28412213 )
2017
11
The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. ( 28255023 )
2017
12
From the observation of atypical cells on blood smear to the diagnosis of mast cell leukemia: a case report in a 79 year old woman consulting for anemia. ( 29043985 )
2017
13
Aleukemic mast cell leukemia associated with chronic myelomonocytic leukemia and chronic lymphocytic leukemia. ( 29122774 )
2017
14
Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome. ( 28599188 )
2017
15
Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia. ( 26876592 )
2016
16
A scientific treatment approach for acute mast cell leukemia: using a strategy based on next-generation sequencing data. ( 27104187 )
2016
17
Extramedullary Involvement of Mast Cell Leukemia Detected by 18F-FDG PET/CT. ( 26975014 )
2016
18
Application of next generation sequencing in the diagnosis and management of mast cell leukemia. ( 27104182 )
2016
19
De novo leukemic variant of mast cell leukemia with KIT D816V. ( 25729733 )
2015
20
Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia. ( 26055303 )
2015
21
Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features. ( 25443885 )
2015
22
Mast cell leukemia: an extremely rare disease. ( 25028296 )
2014
23
Mast cell leukemia associated with undefined morphology and chronic basophilic leukemia. ( 25264491 )
2014
24
Mast cell leukemia with prolonged survival on PKC412/midostaurin. ( 25031773 )
2014
25
FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H. ( 24596674 )
2014
26
Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage. ( 25209843 )
2014
27
Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. ( 24675021 )
2014
28
Mast cell leukemia. ( 23243287 )
2013
29
A case of de novo aleukemic mast cell leukemia without c-KIT mutations in exons 8 and 17. ( 24034180 )
2013
30
The transcriptome of the human mast cell leukemia cells HMC-1.2: an approach to identify specific changes in the gene expression profile in KitD816V systemic mastocytosis. ( 23504229 )
2013
31
A case of systemic mastocytosis associated with acute myeloid leukemia terminating as aleukemic mast cell leukemia after allogeneic hematopoietic stem cell transplantation. ( 23483057 )
2013
32
Sustained paranoid psychosis in a patient with mast cell leukemia and decreased serotonin level. ( 23793328 )
2013
33
Systemic mastocytosis: progressive evolution of an occult disease into fatal mast cell leukemia: unique findings on an unusual hematological neoplasm. ( 22661384 )
2012
34
Mast-cell leukemia exome sequencing reveals a mutation in the IgE mast-cell receptor I^ chain and KIT V654A. ( 22173243 )
2012
35
Death from mast cell leukemia: a young patient with longstanding cutaneous mastocytosis evolving into fatal mast cell leukemia. ( 22329485 )
2012
36
Aleukemic variant of mast cell leukemia. ( 22482127 )
2012
37
Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor. ( 22324351 )
2012
38
Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. ( 21261503 )
2011
39
The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD). ( 20688965 )
2010
40
Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge. ( 20658589 )
2010
41
Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells. ( 20485374 )
2010
42
Mast cell leukemia with rapidly progressing portal hypertension. ( 19883434 )
2009
43
KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia. ( 17949810 )
2008
44
Mast cell leukemia: a report of ten cases. ( 18172645 )
2008
45
Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemia. ( 16543062 )
2006
46
Cladribine therapy in a patient with an aleukemic subvariant of mast cell leukemia. ( 15928938 )
2005
47
Expression of a constitutively active mutant of M-Ras in normal bone marrow is sufficient for induction of a malignant mastocytosis/mast cell leukemia, distinct from the histiocytosis/monocytic leukemia induced by expression of activated H-Ras. ( 15735740 )
2005
48
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. ( 15972446 )
2005
49
Aleukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816V. ( 15512820 )
2004
50
Mast cell leukemia. ( 12564414 )
2003

Variations for Mast-Cell Leukemia

Expression for Mast-Cell Leukemia

Search GEO for disease gene expression data for Mast-Cell Leukemia.

Pathways for Mast-Cell Leukemia

Pathways related to Mast-Cell Leukemia according to KEGG:

37
# Name Kegg Source Accession
1 PI3K-Akt signaling pathway hsa04151

Pathways related to Mast-Cell Leukemia according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.52 BTK CCL2 CCL5 KDR KIT KITLG
2
Show member pathways
13.37 BTK CCL2 CCL5 KDR KIT NTRK3
3
Show member pathways
13.1 BTK CCL2 CCL5 KDR KIT KITLG
4
Show member pathways
13.07 CCL2 CCL5 KIT KITLG RASGRP4
5
Show member pathways
13.02 BTK KDR KIT KITLG NTRK3
6
Show member pathways
12.85 BTK CCL2 CCL5 KDR KIT KITLG
7
Show member pathways
12.72 BTK KDR KIT KITLG NTRK3
8
Show member pathways
12.68 CCL2 KDR KIT KITLG NTRK3
9 12.46 KDR KIT KITLG RASGRP4
10
Show member pathways
12.4 KDR KIT KITLG RASGRP4
11
Show member pathways
12.23 BTK CCL2 CCL5 KDR KIT KITLG
12
Show member pathways
11.91 BTK KIT KITLG
13 11.87 BTK CCL2 CCL5 KIT KITLG
14 11.84 BTK KDR KIT KITLG
15
Show member pathways
11.67 BTK CCL2 CCL5 KDR KITLG
16 11.26 KIT KITLG
17 11.18 KIT KITLG
18 10.68 KIT KITLG

GO Terms for Mast-Cell Leukemia

Cellular components related to Mast-Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.86 ATP7A BTK KDR KIT KITLG NTRK3
2 cytoplasm GO:0005737 9.81 ATP7A BTK CCL5 KDR KIT KITLG
3 membrane raft GO:0045121 9.5 ATP7A BTK KDR
4 receptor complex GO:0043235 9.13 KDR KIT NTRK3
5 mast cell granule GO:0042629 8.62 BTK KIT

Biological processes related to Mast-Cell Leukemia according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.95 BTK KDR KIT NTRK3
2 negative regulation of apoptotic process GO:0043066 9.92 KDR KIT KITLG NTRK3
3 positive regulation of cell proliferation GO:0008284 9.91 KDR KIT KITLG NTRK3
4 cell differentiation GO:0030154 9.91 BTK KDR KIT NTRK3 RASGRP4 SYT1
5 protein phosphorylation GO:0006468 9.88 BTK CCL2 KDR KIT NTRK3
6 regulation of cell shape GO:0008360 9.77 CCL2 KDR KIT
7 positive regulation of MAPK cascade GO:0043410 9.76 KDR KIT NTRK3
8 positive regulation of cell migration GO:0030335 9.76 CCL5 KDR KIT NTRK3
9 negative regulation of signal transduction GO:0009968 9.74 KDR KIT NTRK3
10 cell chemotaxis GO:0060326 9.7 CCL2 CCL5 KIT
11 positive regulation of kinase activity GO:0033674 9.69 KDR KIT NTRK3
12 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.67 CCL5 KDR KIT
13 protein autophosphorylation GO:0046777 9.67 BTK KDR KIT NTRK3
14 peptidyl-tyrosine autophosphorylation GO:0038083 9.66 BTK KDR
15 monocyte chemotaxis GO:0002548 9.65 CCL2 CCL5
16 pigmentation GO:0043473 9.65 ATP7A KIT
17 MAPK cascade GO:0000165 9.65 CCL2 CCL5 KIT KITLG RASGRP4
18 ovarian follicle development GO:0001541 9.64 KIT KITLG
19 lymphocyte chemotaxis GO:0048247 9.64 CCL2 CCL5
20 cellular response to fibroblast growth factor stimulus GO:0044344 9.63 CCL2 CCL5
21 lipopolysaccharide-mediated signaling pathway GO:0031663 9.63 CCL2 CCL5
22 positive regulation of JAK-STAT cascade GO:0046427 9.62 CCL5 KIT
23 peptidyl-tyrosine phosphorylation GO:0018108 9.62 BTK KDR KIT NTRK3
24 eosinophil chemotaxis GO:0048245 9.61 CCL2 CCL5
25 positive regulation of Ras protein signal transduction GO:0046579 9.59 KITLG RASGRP4
26 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.58 CCL2 KDR
27 protein kinase B signaling GO:0043491 9.58 CCL2 CCL5 KDR
28 macrophage chemotaxis GO:0048246 9.56 CCL2 CCL5
29 positive regulation of positive chemotaxis GO:0050927 9.55 KDR NTRK3
30 ectopic germ cell programmed cell death GO:0035234 9.54 KIT KITLG
31 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.35 CCL2 CCL5 KDR KIT NTRK3
32 embryonic hemopoiesis GO:0035162 9.33 KDR KIT KITLG
33 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.02 BTK KDR KIT NTRK3 RASGRP4

Molecular functions related to Mast-Cell Leukemia according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.91 ATP7A BTK KDR KIT NTRK3
2 kinase activity GO:0016301 9.78 BTK KDR KIT NTRK3
3 cytokine activity GO:0005125 9.63 CCL2 CCL5 KITLG
4 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.58 KIT KITLG RASGRP4
5 MAP kinase kinase kinase activity GO:0004709 9.5 KDR KIT NTRK3
6 growth factor binding GO:0019838 9.49 KDR KIT
7 CCR chemokine receptor binding GO:0048020 9.43 CCL2 CCL5
8 mitogen-activated protein kinase kinase binding GO:0031434 9.43 KDR KIT NTRK3
9 obsolete signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.37 KDR KIT
10 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 KDR KIT NTRK3
11 protein tyrosine kinase activity GO:0004713 9.26 BTK KDR KIT NTRK3
12 protein kinase activity GO:0004672 9.1 BTK CCL2 CCL5 KDR KIT NTRK3

Sources for Mast-Cell Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....